Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Am J Kidney Dis. 2020 Jun;75(6):887-896. doi: 10.1053/j.ajkd.2019.09.008. Epub 2019 Dec 6.
RATIONALE & OBJECTIVE: Influenza vaccination is recommended for all adults but particularly for older adults and those with high-risk conditions. Reduced kidney function is an important high-risk condition, but the effectiveness of influenza vaccination across kidney function is uncharacterized. We assessed the effectiveness of influenza vaccination among older adults with and without reduced kidney function.
Observational cohort study.
SETTING & PARTICIPANTS: 454,634 person-seasons among 110,968 individuals 65 years or older in the Geisinger Health System between the 2005 and 2015 influenza seasons, with baseline characteristics matched between those with and without vaccination using inverse probability weighting.
Status of influenza vaccination.
Incident hospitalization with pneumonia/influenza, coronary heart disease, and heart failure during influenza season stratified by estimated glomerular filtration rate (eGFR; ≥ 60, 30-59, and < 30mL/min/1.73m).
Pooled logistic regression analysis to estimate adjusted ORs.
In the 2014-2015 influenza season, the prevalence of influenza vaccination was 63.3% without evident difference across eGFR categories. The incidence of hospitalization was higher in lower eGFRs (eg, 2.2% per person-season among those not vaccinated with eGFR < 30 vs 0.7% with ≥ 60mL/min/1.73m for pneumonia/influenza). Overall, influenza vaccination was associated with lower odds of hospitalization with pneumonia/influenza (OR, 0.86; 95% CI, 0.79-0.93), coronary heart disease (OR, 0.93; 95% CI, 0.88-0.97), and heart failure (OR, 0.92; 95% CI, 0.86-0.99). When assessing by eGFR categories, the association was consistent in eGFR ≥ 30, but not significant in < 30mL/min/1.73m (ORs of 1.04 [95% CI, 0.79-1.36] for pneumonia/influenza, 1.03 [95% CI, 0.87-1.23] for coronary heart disease, and 1.10 [95% CI, 0.92-1.33] for heart failure).
Possible unmeasured confounding.
Influenza vaccination was associated with lower risk for hospitalizations with pneumonia/influenza and major cardiac diseases in eGFR ≥ 30mL/min/1.73m. Studies are needed to explore optimal vaccination strategies for eGFR < 30mL/min/1.73m.
流感疫苗推荐用于所有成年人,尤其是老年人和有高危情况的人。肾功能下降是一个重要的高危情况,但肾功能不全者接种流感疫苗的效果尚未明确。我们评估了老年人群中肾功能正常和下降者接种流感疫苗的效果。
观察性队列研究。
在 2005 年至 2015 年流感季节期间,110968 名 65 岁或以上的个体中有 454634 人-季节,在 Geisinger 健康系统中,通过逆概率加权法在有和没有疫苗接种的个体之间匹配基线特征。
流感疫苗接种情况。
流感季节中肺炎/流感、冠心病和心力衰竭的住院发生率,按估计肾小球滤过率(eGFR;≥60、30-59 和<30mL/min/1.73m)分层。
采用汇总逻辑回归分析估计调整后的比值比(OR)。
在 2014-2015 年流感季节,流感疫苗接种率在 eGFR 分类中没有明显差异,为 63.3%。较低的 eGFR 与更高的住院发生率相关(例如,未接种疫苗的 eGFR<30 的人群每 1 人-季节的住院率为 2.2%,而 eGFR≥60 的人群为 0.7%)。总体而言,流感疫苗接种与肺炎/流感(OR,0.86;95%CI,0.79-0.93)、冠心病(OR,0.93;95%CI,0.88-0.97)和心力衰竭(OR,0.92;95%CI,0.86-0.99)的住院风险降低相关。当按 eGFR 分类评估时,在 eGFR≥30 的情况下,这种关联是一致的,但在 eGFR<30mL/min/1.73m 时并不显著(肺炎/流感的 OR 为 1.04[95%CI,0.79-1.36],冠心病为 1.03[95%CI,0.87-1.23],心力衰竭为 1.10[95%CI,0.92-1.33])。
可能存在未测量的混杂因素。
在 eGFR≥30mL/min/1.73m 的情况下,流感疫苗接种与肺炎/流感和主要心脏疾病的住院风险降低相关。需要研究来探索 eGFR<30mL/min/1.73m 的最佳疫苗接种策略。